The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer.

Inflammatory breast cancer is a rare but lethal form of locally advanced breast cancer. Despite improvements in survival with the advent of multidisciplinary treatment regimens, 5-year survival rates remain disappointing, at approximately 30%. Numerous molecular markers have been investigated for their potential as useful prognostic and predictive markers of treatment response that would impact on the management of inflammatory breast cancer. This review discusses the current status of p53 mutations both as a prognostic marker and as a potential target for directed therapies.

[1]  J. Roth.  Adenovirus p53 gene therapy , 2006, Expert opinion on biological therapy.

[2]  H. Pandha,et al.  Adenoviral strategies for the gene therapy of cancer. , 2005, Seminars in oncology.

[3]  Zhao-hui Peng,et al.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.

[4]  F. Bertucci,et al.  Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.

[5]  S. Steinberg,et al.  Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Rosette Lidereau,et al.  Molecular Profiling of Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[7]  G. Hortobagyi,et al.  p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[8]  G. Hortobagyi,et al.  Prognostic value of P53, MDM‐2, and MUC‐1 for patients with inflammatory breast carcinoma , 2004, Cancer.

[9]  Y. Yen,et al.  Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. , 2004, Journal of Clinical Oncology.

[10]  F. Bertucci,et al.  Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment , 2004, Bone Marrow Transplantation.

[11]  S. Merajver,et al.  Validation of a Tissue Microarray to Study Differential Protein Expression in Inflammatory and Non-Inflammatory Breast Cancer , 2004, Breast Cancer Research and Treatment.

[12]  K. Do,et al.  Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer , 2004, Clinical Cancer Research.

[13]  T. Whelan,et al.  Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer , 2004, Canadian Medical Association Journal.

[14]  F. Bertucci,et al.  Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’ , 2004, The Journal of pathology.

[15]  U. Moll,et al.  The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.

[16]  K. Wiman,et al.  Small molecules that reactivate mutant p53. , 2003, European journal of cancer.

[17]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Dinney,et al.  Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. J. van de Vijver,et al.  Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  S. Steinberg,et al.  Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. Espié,et al.  Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer , 2002, Oncogene.

[22]  M. Konstadoulakis,et al.  Molecular markers in breast cancer: can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors? , 2002, Breast.

[23]  J. Doroshow,et al.  Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer , 2002, British Journal of Cancer.

[24]  S. Barsky,et al.  Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma , 2002, Oncogene.

[25]  Galina Selivanova,et al.  Characterization of the p53-rescue drug CP-31398 in vitro and in living cells , 2002, Oncogene.

[26]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[27]  I. Brukner.  INGN-201. Introgen Therapeutics. , 2001, Current opinion in investigational drugs.

[28]  M. Rahbar,et al.  Case Control Study of Prognostic Markers and Disease Outcome in Inflammatory Carcinoma Breast: A Unique Clinical Experience , 2001, The breast journal.

[29]  J. Roth,et al.  Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. , 2001, Seminars in oncology.

[30]  M. Redston,et al.  p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. , 2001, Journal of the National Cancer Institute.

[31]  R. Herrmann,et al.  Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Tofilon,et al.  Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. , 2000, International journal of radiation oncology, biology, physics.

[33]  T. Nukiwa,et al.  Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. , 2000, Cancer letters.

[34]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[35]  J. Bergh,et al.  Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors , 2000, Cancer Gene Therapy.

[36]  M. Piccart,et al.  The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  T. Soussi.  The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation , 2000, Annals of the New York Academy of Sciences.

[38]  E. Shpall,et al.  Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Fersht,et al.  Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations , 2000, The EMBO journal.

[40]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[41]  S. Barsky,et al.  A novel human xenograft model of inflammatory breast cancer. , 1999, Cancer research.

[42]  C Caldas,et al.  Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis , 1999, British Journal of Cancer.

[43]  G. Clayman,et al.  Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. , 1999, Journal of the National Cancer Institute.

[45]  B. Gusterson,et al.  Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions , 1999, Oncogene.

[46]  A. Salomon,et al.  p53 mutation as a genetic trait of typical medullary breast carcinoma. , 1999, Journal of the National Cancer Institute.

[47]  I. Andrulis,et al.  Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. , 1999, Journal of the National Cancer Institute.

[48]  S. Lippman,et al.  Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  W. El-Deiry,et al.  Acute overexpression of wt p53 facilitates anticancer drug‐induced death of cancer and normal cells , 1998, International journal of cancer.

[50]  M. J. van de Vijver,et al.  p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  P. Seth,et al.  A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers. , 1997, Cancer gene therapy.

[52]  B. Groner,et al.  Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain , 1997, Nature Medicine.

[53]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[54]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[55]  L. Holmberg,et al.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. , 1996, Journal of the National Cancer Institute.

[56]  T. McDonnell,et al.  Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. , 1995, Cancer research.

[57]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[58]  J. Roth,et al.  Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. , 1994, Journal of the National Cancer Institute.

[59]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[60]  H. Shepard,et al.  Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. , 1994, Human gene therapy.

[61]  J. Blondal,et al.  The role of p53 in tumor progression. , 1994, Seminars in cancer biology.

[62]  M. Espié,et al.  p53 mutations and overexpression in locally advanced breast cancers. , 1994, British Journal of Cancer.

[63]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[64]  A. Levine,et al.  Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. , 1993, Journal of the National Cancer Institute.

[65]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[66]  A. Levine,et al.  Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[67]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[68]  G. Hortobagyi,et al.  Inflammatory breast cancer: a review. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  P. Shaw,et al.  Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[70]  G. Cocconi,et al.  Neoadjuvant Chemotherapy or Chemotherapy and Endocrine Therapy in Locally Advanced Breast Carcinoma: A Prospective, Randomized Study , 1990, American journal of clinical oncology.

[71]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[72]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[73]  S. Steinberg,et al.  Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. , 1987, Cancer research.

[74]  L. M. Toonkel,et al.  Locally advanced breast carcinoma: results with combined regional therapy. , 1986, International journal of radiation oncology, biology, physics.

[75]  Atkins Hl,et al.  Treatment of locally advanced carcinoma of the breast with roentgen therapy and simple mastectomy. , 1961 .

[76]  W. McGuire,et al.  Prognostic significance of p53 gene alterations in node-negative breast cancer , 2004, Breast Cancer Research and Treatment.

[77]  J. Gu,et al.  Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  J. Roth,et al.  P53 gene replacement for cancer--interactions with DNA damaging agents. , 2001, Acta oncologica.

[79]  T. Iwanaga,et al.  Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. , 2001, Cancer research.